Merck KGaA (MKGAF) Stock Price, News & Analysis

Company Overview

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

Key Stats

• Today's Range: $121.72 to $128.32
• 50-Day Range: $119.00 to $137.00
• 52-Week Range: $118.05 to $200.56
• Volume: 351 shs
• Average Volume: 1,081 shs
• Market Capitalization: $15.88 billion
• P/E Ratio: 18.76
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

Merck KGaA Stock Analysis - MarketRank™

Merck KGaA scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Merck KGaA.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 8.21%

Earnings Growth

Earnings for Merck KGaA are expected to grow by 8.21% in the coming year, from $9.75 to $10.55 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Merck KGaA is 18.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.85.

Price to Earnings Ratio vs. Sector

The P/E ratio of Merck KGaA is 18.76, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.12.

Price to Book Value per Share Ratio

Merck KGaA has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.42% of the outstanding shares of Merck KGaA have been sold short.

Short Interest Ratio / Days to Cover

Merck KGaA has a short interest ratio ("days to cover") of 492.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Merck KGaA has recently decreased by 1.56%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Merck KGaA does not currently pay a dividend.

Dividend Growth

Merck KGaA does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.42% of the outstanding shares of Merck KGaA have been sold short.

Short Interest Ratio / Days to Cover

Merck KGaA has a short interest ratio ("days to cover") of 492.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Merck KGaA has recently decreased by 1.56%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.93

News Sentiment

Merck KGaA has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Merck KGaA this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Merck KGaA insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 0.10% of the stock of Merck KGaA is held by institutions.

MKGAF Stock Analysis - Frequently Asked Questions

How have MKGAF shares performed this year?

Merck KGaA's stock was trading at $151.56 at the beginning of the year. Since then, MKGAF shares have decreased by 18.9% and is now trading at $122.8620.

How do I buy shares of Merck KGaA?

Shares of MKGAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:MKGAF
• CIK: N/A
• Web: www.merckgroup.com
• Phone: 496151720
• Fax: 49-61-5172-2000
• Employees: 62,908
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $6.81
• Trailing P/E Ratio: 18.76
• Forward P/E Ratio: 12.60
• P/E Growth: N/A
• Net Income: $3.06 billion
• Net Margins: 12.60%
• Pretax Margin: 15.64%
• Return on Equity: 10.17%
• Return on Assets: 5.74%

Debt

• Debt-to-Equity Ratio: 0.27
• Current Ratio: 1.31
• Quick Ratio: 0.84

Sales & Book Value

• Annual Sales: $22.72 billion
• Price / Sales: 0.70
• Cash Flow: $37.01 per share
• Price / Cash Flow: 3.32
• Book Value: $212.00 per share
• Price / Book: 0.58

Miscellaneous

• Outstanding Shares: 129,240,000
• Free Float: N/A
• Market Cap: $15.88 billion
• Optionable: Not Optionable
• Beta: 0.96